• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Lupin gets warning letter from US FDA for Somerset facility

expresspharmaJune 16, 2021

Tag: lupin , FDA , Lupin Somerset

Lupin has received a warning letter from the US FDA for the company’s Somerset, New Jersey facility. The US FDA had inspected the Lupin Somerset site from September 10, 2020, to November 5, 2020.

A statement from Lupin informed, “The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility. We are committed to addressing the concerns raised by the US FDA and will work with the FDA and the New Jersey District to resolve these issues at the earliest.”

Previous:Natco gets US FDA approval for Carfilzomib vials

Next:Training healthcare workers and pharmacists against fraudulent medicines is a must: ASPA

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Lupin gets warning letter from US FDA for Somerset facility | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

filter integrity testing fda guidelines

filter integrity testing fda guidelines
Ramantadine( FDA)

Ramantadine( FDA)
Lupeol-8%-Lupinus Albus Extracts

Lupeol-8%-Lupinus Albus Extracts
Semaglutide(FDA)

Semaglutide(FDA)
Hemisuccinate /Sodium (FDA/DMF)

Hemisuccinate /Sodium (FDA/DMF)
HFHA(m-6FDAP)

HFHA(m-6FDAP)
Naproxen/ Sodium salt (FDA/COS)

Naproxen/ Sodium salt (FDA/COS)
Deltamine (FDA)

Deltamine (FDA)
Mesnaum (FDA)

Mesnaum (FDA)
Daunomycin HCL( FDA)

Daunomycin HCL( FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service